CryoPort (CYRX) AI Stock Analysis

• Market Cap: $358.48M
• Dividend Yield: N/A
• Average Volume (3M): 517.43K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.28
• Revenue Growth: -4.53%
• EPS Growth: 5.24%
• Country: US
• Employees: 1,090
• Sector: Industrials
• Sector Strength: 90
• Industry: Integrated Freight & Logistics
• EPS (TTM): -0.28
• Shares Outstanding: 50,137,220
• 10 Day Avg. Volume: 486,573
• 30 Day Avg. Volume: 517,432
• PEG Ratio: -0.10
• Price to Book (P/B): 0.75
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -8.94
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $10.44
• Price Target Upside: 49.57% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 9

CryoPort's overall stock score reflects its financial challenges, despite some technical momentum and positive strategic moves highlighted in its latest earnings call. The company's significant losses and liquidity issues weigh heavily on the score, while the strategic partnership with DHL and projected revenue growth provide a counterbalance. The valuation remains a concern due to the negative P/E ratio and lack of dividends.

Positive Factors

Financial Performance

CYRX reported revenue of $41M, slightly ahead of expectations, with services growth leading the way at 17%, setting up the company well to meet its revenue guidance.

Profitability

Gross margin showed meaningful year-over-year expansion, boosting confidence in CYRX's ability to deliver on adjusted EBITDA.

Negative Factors

Revenue Estimates

CYRX's revenue estimates for 2025 and 2026 have been reduced, indicating potential challenges in achieving previously anticipated growth.

Tariffs

Steel and aluminum tariffs of 25% have gone into effect, but the full impact on CYRX's results is not yet reflected, posing a concern for future profitability.

CryoPort Business Overview & Revenue Model

Company Description

Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle. It also provides information dashboards and validation documentation for shipments through data collected by the SmartPak Condition Monitoring System; and vacuum insulated aluminum dewars and cryogenic freezers systems. In addition, the company offers biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; transportation of frozen biological specimens to and from customer locations; and management of incoming and outgoing biological specimens, as well as provides logistics support and management; and short-term logistics and engineering consulting services. It serves biopharma/pharma, animal health, and human reproductive medicine markets. The company was founded in 1999 and is headquartered in Brentwood, Tennessee.

How the Company Makes Money

CryoPort generates revenue primarily through its temperature-controlled logistics services, which are offered to clients in the life sciences industry. Key revenue streams include transportation and logistics services for cell and gene therapy companies, biopharmaceutical companies, and research organizations. These services are supported by CryoPort's proprietary Cryoport Express® Shippers, Cryoport Certified™ Logistics Centers, and advanced monitoring systems that ensure the safe and secure shipment of temperature-sensitive materials. The company also benefits from long-term partnerships and contracts with leading biopharmaceutical companies and research institutions, which provide a stable and recurring revenue base. Additionally, CryoPort's acquisitions in the logistics and supply chain sectors have expanded its service portfolio, contributing to its overall earnings.

CryoPort Financial Statement Overview

Summary

CryoPort faces significant financial challenges with declining revenues, persistent losses, and strained cash flow. While the balance sheet shows some stability in leverage, the company struggles with profitability and liquidity, potentially impacting its ability to sustain operations without strategic changes or external support.

Income Statement

CryoPort has experienced declining revenues with a 2% decrease from 2023 to 2024. The company faces significant profitability challenges, with a negative net profit margin of -53.7% and negative EBIT and EBITDA margins, indicating operational inefficiencies. The consistent decline in gross profit margin, standing at 43.6% for 2024, further reflects pressure on maintaining profitability.

Balance Sheet

The balance sheet shows a moderate level of financial stability, with a debt-to-equity ratio of 0.62, indicating a manageable level of leverage. However, the return on equity remains negative, reflecting ongoing net losses. The equity ratio is 57.1%, suggesting a reasonable proportion of equity financing. Overall, the balance sheet exhibits a stable but strained financial position.

Cash Flow

Cash flow analysis reveals negative free cash flow, highlighting liquidity challenges. Although operating cash flow has worsened from -$0.76 million in 2023 to -$16.3 million in 2024, the free cash flow to net income ratio remains negative. The negative operating cash flow to net income ratio also underscores ongoing operational cash burn.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
228.38M	233.25M	237.28M	222.61M	78.70M
	Gross Profit
99.63M	99.33M	103.87M	96.58M	36.33M
	EBIT
-130.87M	-115.16M	-31.90M	-17.83M	-30.01M
	EBITDA
-78.61M	-66.36M	-6.19M	-248.91M	-20.31M
	Net Income Common Stockholders
-122.76M	-99.59M	-37.33M	-275.53M	-32.69M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
261.75M	456.75M	523.32M	628.80M	93.32M
	Total Assets
703.49M	957.74M	1.04B	1.11B	552.40M
	Total Debt
250.70M	416.00M	435.91M	427.06M	130.92M
	Net Debt
205.41M	369.66M	399.31M	287.95M	94.05M
	Total Liabilities
301.59M	468.72M	482.91M	471.14M	169.71M
	Stockholders Equity
401.90M	489.02M	555.84M	641.83M	382.70M
Cash Flow		Free Cash Flow
-33.58M	-45.66M	-26.05M	-16.88M	-24.54M
	Operating Cash Flow
-16.32M	-757.00K	-1.85M	8.13M	-14.87M
	Investing Cash Flow
176.81M	36.05M	-59.68M	-469.25M	-382.31M
	Financing Cash Flow
-161.53M	-23.80M	-39.17M	564.34M	385.58M

CryoPort Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.98
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CYRX, the sentiment is Positive. The current price of 6.98 is above the 20-day moving average (MA) of 5.92, above the 50-day MA of 5.95, and below the 200-day MA of 7.27, indicating a neutral trend. The MACD of 0.26 indicates Negative momentum. The RSI at 64.69 is Neutral, neither overbought nor oversold. The STOCH value of 83.11 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CYRX.

CryoPort Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RLGT	70 Outperform	$290.98M	18.57	8.09%	―	7.18%	186.98%
Sector *	64 Neutral	$4.38B	12.03	5.25%	249.91%	4.11%	-11.02%
CYRX	54 Neutral	$358.48M	―	-24.08%	―	-4.53%	5.24%
FWRD	53 Neutral	$578.95M	―	-147.96%	0.86%	50.11%	-682.50%
CRGO	52 Neutral	$111.35M	―	-23.18%	―	49.48%	80.17%
AIRT	45 Neutral	$46.67M	―	-13.52%	―	3.36%	94.32%
FLX	41 Neutral	$169.29M	124.65	-49.98%	―	-2.76%	-586.31%

CryoPort Corporate Events

CryoPort Sells CRYOPDP to DHL for $138 Million

On March 31, 2025, Cryoport, Inc. announced the sale of its global specialty courier business, CRYOPDP, to DHL Supply Chain International Holding B.V. for approximately $138 million in cash, based on a total enterprise value of $195 million. This transaction, expected to close in the second or third quarter of 2025, will enhance DHL’s capabilities in specialized pharma logistics and supports its strategy to lead in life science and healthcare logistics. The strategic partnership between Cryoport and DHL aims to strengthen their supply chain service offerings for the global life sciences and healthcare sector, with Cryoport focusing on expanding its business in EMEA and APAC regions.